GENERAL20 Sept 2026
Top 10 pharma firms sustain volume growth as smaller rivals struggle
India's top ten pharma companies kept growing their sales volumes through August 2026, while smaller rivals saw volumes fall. This affects medicine makers, distributors and stockists. Sales are shifting towards chronic therapies, so smaller players may find the market harder. If you deal in pharma, watch your product mix and keep your GST and tax records tidy.
Key Statutory Highlights
- The top 10 pharma companies in India sustained positive volume growth through August 2026, while smaller rivals faced declining volumes.
- The shift towards chronic therapies is a key reason behind this gap between large and small pharma players.
- The top 10 in August included Sun Pharma, Cipla, Abbott, Mankind Pharma, Torrent Pharmaceuticals, Alkem Laboratories, Intas Pharmaceuticals, Lupin, Zydus Lifesciences and Dr Reddy's Laboratories.
Actionable Advice for Taxpayers / Founders:If you supply or distribute pharma products, review your product mix and stock arrangements, and speak to your tax advisor about how a change in your sales pattern may affect your GST and income tax position.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: